Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a late-stage trial

Key Highlights

• Retatrutide is a next-generation weight-loss drug developed by Eli Lilly.
• The drug resulted in significant weight loss in late-stage clinical trials.
• Participants also experienced reduced knee pain as a benefit of the treatment.
• Retatrutide targets three hormones in the body.
• It has shown more efficacy in weight loss than any approved drug to date.